Charytan DM, et al. - Among subjects with clinically evident atherosclerosis and low-density lipoprotein cholesterol (LDL-C) ≥70 mg/dl or non–high-density lipoprotein cholesterol ≥100 mg/dl, researchers compared the outcomes with evolocumab vs placebo, based on kidney function, in the FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial. Participants were randomized to evolocumab or placebo. Patients with preserved kidney function, with stage 2 chronic kidney disease (CKD), and with ≥stage 3 CKD were 8,077, 15,034, and 4,443, respectively. Across CKD groups, consistent outcomes were reported with regard to LDL-C lowering and relative clinical efficacy and safety of evolocumab vs placebo. With more advanced CKD, numerically greater absolute attenuation in the composite of cardiovascular death, MI, or stroke was achieved with evolocumab.